Isatuximab, carfilzomib, and dexamethasone in patients with relapsed multiple myeloma: updated results from IKEMA, a randomized Phase 3 study.

Blood Cancer J · 2023 · PMC10166682 · PMID 37156782

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

showed a trendno p-value reported

Nonetheless, in the current updated analysis, descriptive OS showed a trend in favor of Isa-Kd vs Kd with HR of 0.78 (95% CI: 0.54–1.12) (Supplementary Table S4 ).

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.